Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester)
Hematopoietic And Lymphoid Cell Neoplasm
Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04874194CT.gov Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hematopoietic And Lymphoid Cell Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester) (this asset) | M.D. Anderson Cancer Center | P1/2 | CC · 47 |
| Pegloticase | M.D. Anderson Cancer Center | P4 | BB |
| Nivestim | St. Jude Children's Research Hospital | P2 | BB |
| Rasburicase | M.D. Anderson Cancer Center | P4 | BB |
| Prednisone | M.D. Anderson Cancer Center | P2 | BB |
| Methotrexate | Therapeutic Advances in Childhood Leukemia Consortium | P2 | BB |
| Hydromorphon | M.D. Anderson Cancer Center | P4 | BB |
| Cyclosporin A | Children's Oncology Group | P3 | BB |
| Fludarabine | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Hematopoietic And Lymphoid Cell Neoplasm cohort
Other indications for Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P3 | B · 59 |
| Leukemia | — | P2 | B · 58 |
| Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester) in Hematopoietic And Lymphoid Cell Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cephalotaxine-4-methyl-2r-2-hydroxy-2-4-hydroxy-4-methylpentylbutanedioate-ester-hematopoietic-and-lymphoid-cell-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →